Passage BIO (PASG) Income from Continuing Operations (2019 - 2026)
Passage BIO (PASG) posted quarterly Income from Continuing Operations of 15694000.0 for Q1 2026, up 50.27% year-over-year from 10444132.27 in Q1 2025, and up 42.17% quarter-over-quarter from 27137000.0 in Q4 2025.
Passage BIO (PASG) Income from Continuing Operations (2019 - 2026) Analysis & Trends
Passage BIO's Income from Continuing Operations history runs 8 years deep, the most recent figure standing at 15694000.0 for Q1 2026.
- In Q1 2026, Income from Continuing Operations rose 50.27% year-over-year to 15694000.0; the TTM figure through Mar 2026 stood at 139247000.0 (up 61.65% YoY), while the FY2025 annual figure was 272056000.0, up 6.25% from the prior year.
- Income from Continuing Operations for Q1 2026 stood at 15694000.0, up from 27137000.0 in the prior quarter.
- The five-year high for Income from Continuing Operations was 15694000.0 in Q1 2026, with the low at 234127000.0 in Q4 2024.
- The 5-year median for Income from Continuing Operations is 55502000.0 (2023), against an average of 82234705.88.
- The sharpest annual moves came in 2022 and 2025: Income from Continuing Operations plunged 121.83% in 2022, then soared 88.41% in 2025.
- Passage BIO's Income from Continuing Operations stood at 207585000.0 in 2022, then decreased by 5.53% to 219071000.0 in 2023, then retreated by 6.87% to 234127000.0 in 2024, then jumped by 88.41% to 27137000.0 in 2025, then surged by 42.17% to 15694000.0 in 2026.
- Business Quant data shows PASG's Income from Continuing Operations at 15694000.0 in Q1 2026, 27137000.0 in Q4 2025, and 46872000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 482.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -782.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 237.01 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 164.49 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -174.37 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -13.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 81.49 Mn |
| 10 | Passage BIO | 13.99 Mn | 13.99 Mn | - | -8.27 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -8.27 Mn |
| Mar 31, 2026 | -15.69 Mn |
| Dec 31, 2025 | -27.14 Mn |
| Sep 30, 2025 | -46.87 Mn |
| Jun 30, 2025 | -49.54 Mn |
| Mar 31, 2025 | -31.56 Mn |
| Dec 31, 2024 | -234.13 Mn |
| Sep 30, 2024 | -36.94 Mn |
| Jun 30, 2024 | -60.50 Mn |
| Mar 31, 2024 | -62.16 Mn |
| Dec 31, 2023 | -219.07 Mn |
| Sep 30, 2023 | -73.90 Mn |
| Jun 30, 2023 | -44.81 Mn |
| Mar 31, 2023 | -55.50 Mn |
| Dec 31, 2022 | -207.59 Mn |
| Sep 30, 2022 | -48.88 Mn |
| Jun 30, 2022 | -89.65 Mn |
| Mar 31, 2022 | -94.08 Mn |
| Dec 31, 2021 | -186.95 Mn |
| Sep 30, 2021 | -50.47 Mn |